Literature DB >> 23609350

Blood-brain barrier structure and function and the challenges for CNS drug delivery.

N Joan Abbott1.   

Abstract

The neurons of the central nervous system (CNS) require precise control of their bathing microenvironment for optimal function, and an important element in this control is the blood-brain barrier (BBB). The BBB is formed by the endothelial cells lining the brain microvessels, under the inductive influence of neighbouring cell types within the 'neurovascular unit' (NVU) including astrocytes and pericytes. The endothelium forms the major interface between the blood and the CNS, and by a combination of low passive permeability and presence of specific transport systems, enzymes and receptors regulates molecular and cellular traffic across the barrier layer. A number of methods and models are available for examining BBB permeation in vivo and in vitro, and can give valuable information on the mechanisms by which therapeutic agents and constructs permeate, ways to optimize permeation, and implications for drug discovery, delivery and toxicity. For treating lysosomal storage diseases (LSDs), models can be included that mimic aspects of the disease, including genetically-modified animals, and in vitro models can be used to examine the effects of cells of the NVU on the BBB under pathological conditions. For testing CNS drug delivery, several in vitro models now provide reliable prediction of penetration of drugs including large molecules and artificial constructs with promising potential in treating LSDs. For many of these diseases it is still not clear how best to deliver appropriate drugs to the CNS, and a concerted approach using a variety of models and methods can give critical insights and indicate practical solutions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609350     DOI: 10.1007/s10545-013-9608-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  135 in total

1.  In vitro model for evaluating drug transport across the blood-brain barrier.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

2.  Neurodegeneration and the neurovascular unit.

Authors:  Berislav V Zlokovic
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

3.  Targeted delivery of proteins across the blood-brain barrier.

Authors:  Brian J Spencer; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

Review 4.  Circumventricular organs: receptive and homeostatic functions and clinical implications.

Authors:  Eduardo E Benarroch
Journal:  Neurology       Date:  2011-09-20       Impact factor: 9.910

Review 5.  Immunologic privilege in the central nervous system and the blood-brain barrier.

Authors:  Leslie L Muldoon; Jorge I Alvarez; David J Begley; Ruben J Boado; Gregory J Del Zoppo; Nancy D Doolittle; Britta Engelhardt; John M Hallenbeck; Russell R Lonser; John R Ohlfest; Alexandre Prat; Maurizio Scarpa; Richard J Smeyne; Lester R Drewes; Edward A Neuwelt
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-17       Impact factor: 6.200

6.  Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Kim M Hemsley; John J Hopwood
Journal:  J Inherit Metab Dis       Date:  2010-05-07       Impact factor: 4.982

7.  Anti-Aβ-MAb and dually decorated nanoliposomes: effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells.

Authors:  Eleni Markoutsa; Konstantina Papadia; Carla Clemente; Orfeu Flores; Sophia G Antimisiaris
Journal:  Eur J Pharm Biopharm       Date:  2012-02-22       Impact factor: 5.571

8.  Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA.

Authors:  Ainslie L K Roberts; Janice M Fletcher; Lynette Moore; Sharon Byers
Journal:  Mol Genet Metab       Date:  2010-06-22       Impact factor: 4.797

9.  Establishment of a simplified in vitro porcine blood-brain barrier model with high transendothelial electrical resistance.

Authors:  Adjanie Patabendige; Robert A Skinner; N Joan Abbott
Journal:  Brain Res       Date:  2012-07-10       Impact factor: 3.252

10.  Barrier mechanisms in the developing brain.

Authors:  Norman R Saunders; Shane A Liddelow; Katarzyna M Dziegielewska
Journal:  Front Pharmacol       Date:  2012-03-29       Impact factor: 5.810

View more
  249 in total

Review 1.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

2.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Jann N Sarkaria; William F Elmquist
Journal:  Pharmacol Res       Date:  2017-06-17       Impact factor: 7.658

3.  Drug Delivery and Nanoformulations for the Cardiovascular System.

Authors:  W J Geldenhuys; M T Khayat; J Yun; M A Nayeem
Journal:  Res Rev Drug Deliv       Date:  2017-03-07

Review 4.  Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.

Authors:  William Tomaszewski; Luis Sanchez-Perez; Thomas F Gajewski; John H Sampson
Journal:  Clin Cancer Res       Date:  2019-02-25       Impact factor: 12.531

Review 5.  Gene therapy for metachromatic leukodystrophy.

Authors:  Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 6.  Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption.

Authors:  Samuel A Sprowls; Tasneem A Arsiwala; Jacob R Bumgarner; Neal Shah; Sundus S Lateef; Brooke N Kielkowski; Paul R Lockman
Journal:  Trends Cancer       Date:  2019-07-20

Review 7.  Diabetes, adult neurogenesis and brain remodeling: New insights from rodent and zebrafish models.

Authors:  Anne-Claire Dorsemans; David Couret; Anaïs Hoarau; Olivier Meilhac; Christian Lefebvre d'Hellencourt; Nicolas Diotel
Journal:  Neurogenesis (Austin)       Date:  2017-01-31

8.  Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma.

Authors:  Jinhwan Kim; Abhinav Dey; Anshu Malhotra; Jingbo Liu; Song Ih Ahn; Yoshitaka J Sei; Anna M Kenney; Tobey J MacDonald; YongTae Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-15       Impact factor: 11.205

9.  Bazedoxifene protects cerebral autoregulation after traumatic brain injury and attenuates impairments in blood-brain barrier damage: involvement of anti-inflammatory pathways by blocking MAPK signaling.

Authors:  Yu-Long Lan; Xun Wang; Yu-Jie Zou; Jin-Shan Xing; Jia-Cheng Lou; Shuang Zou; Bin-Bin Ma; Yan Ding; Bo Zhang
Journal:  Inflamm Res       Date:  2019-01-31       Impact factor: 4.575

Review 10.  Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents.

Authors:  Xiaohuan Xia; Yi Wang; Yunlong Huang; Han Zhang; Hongfang Lu; Jialin C Zheng
Journal:  Prog Neurobiol       Date:  2019-09-19       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.